High-grade serous ovarian cancer (HGSOC) is notoriously known as the “silent killer” of post-
menopausal women as it has an insidious progression and is the deadliest gynaecological …

Abstract Multi-target Tyrosine Kinase Inhibitors (MTKIs) have drawn substantial attention in
tumor therapy. MTKIs could inhibit tumor cell proliferation and induce apoptosis by blocking …

Lately, attention to combustion synthesis has been encouraged owing to being cost-
effective, rapid, and produces samples with low crystallite sizes and/or different morphology …

Platinum (Pt)-based chemotherapy drugs such as cisplatin are the first line and core options
for the treatment of ovarian cancer (OC), while cisplatin resistance has a worse prognosis …

New liposomes modified with pyrrolidinium surfactants containing a hydroxyethyl fragment
(C n PB, n= 12, 14, 16) were prepared for transdermal delivery of non-steroidal anti …

Abstract Salt‐inducible kinase 2 (SIK2) is a promising target for ovarian cancer therapy due
to its critical role in tumorigenesis and progression. Currently available SIK2 inhibitors have …

Ovarian cancer is a common gynecologic malignancy with a high fatality rate. Intraperitoneal
chemotherapy has been proved as an efficient clinical treatment for disseminated ovarian …

Immune escape is the main cause of the low response rate to immunotherapy for cancer,
including ovarian cancer. Growth differentiation factor-15 (GDF-15) inhibits immune cell …

Treatment of ovarian cancer is challenging due to late stage diagnosis, acquired drug
resistance mechanisms, and systemic toxicity of chemotherapeutic agents. Combination …

Ovarian cancer is a highly lethal disease that affects women. Early diagnosis and treatment
of women with early-stage disease improve the probability of survival. Unfortunately, the …